Lassa fever medical therapy: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) |
m (Changes made per Mahshid's request) |
||
| (4 intermediate revisions by one other user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{YD}}; {{SSK}}; {{Ammu}} | {{CMG}}; {{AE}} {{YD}}; {{SSK}}; {{Ammu}} | ||
==Overview== | ==Overview== | ||
Management of Lassa fever includes supportive care and administration of intravenous (IV) [[ribavirin]]. Data on the efficacy of antiviral agents in Lassa fever are scarce. IV [[ribavirin]] was previously evaluated for treatment of Lassa fever and demonstrated a reduction in mortality when administered anytime during the course of the disease, especially early within the first 6 days of symptom-onset. Ribavirin is administered intravenously for a total of 10 days using the following regimen: first, loading dose of 30 mg/kg (max. 2g) followed by a dose of 16 mg/kg (max. 1g) IV q6h for 4 days, followed by a dose of 8 mg/kg (max. 500mg) IV q8h for 6 days.<ref name="pmid3940312">{{cite journal| author=McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM et al.| title=Lassa fever. Effective therapy with ribavirin. | journal=N Engl J Med | year= 1986 | volume= 314 | issue= 1 | pages= 20-6 | pmid=3940312 | doi=10.1056/NEJM198601023140104 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3940312 }} </ref> In addition to antiviral therapy, management includes supportive care to adequately maintain respiratory status, as well as [[fluid]] and [[electrolyte]] balance. | |||
==Medical Therapy== | ==Medical Therapy== | ||
===Supportive Care=== | |||
* All hospitalized individuals with suspected Lassa fever should be isolated with proper disposal of [[body fluids]] and [[excretion|excreta]]. | * All hospitalized individuals with suspected Lassa fever should be isolated with proper disposal of [[body fluids]] and [[excretion|excreta]]. | ||
* Supportive care, including adequate f[[Fluid replacement|luid]] and electrolyte replacement and [[blood transfusions]], may also be required. | * Supportive care, including adequate f[[Fluid replacement|luid]] and electrolyte replacement and [[blood transfusions]], may also be required. | ||
* Intravenous (IV) [[ribavirin]] is the | ===Antiviral Therapy: Ribavirin=== | ||
* | * Intravenous (IV) [[ribavirin]], an antiviral agent with an effect on viral replication, is associated with a reduction in mortality among patients with Lassa fever, especially when administered within the first 6 days of symptom-onset.<ref name="pmid3940312">{{cite journal| author=McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM et al.| title=Lassa fever. Effective therapy with ribavirin. | journal=N Engl J Med | year= 1986 | volume= 314 | issue= 1 | pages= 20-6 | pmid=3940312 | doi=10.1056/NEJM198601023140104 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3940312 }} </ref> | ||
*Compared with oral ribavirin, intravenous (IV) ribavirin is almost twice as [[effective dose|effective]].<ref>{{cite journal |author=Fisher-Hoch SP, McCormick JB |title=Lassa fever vaccine |journal=Expert review of vaccines |volume=3 |issue=2 |pages=189-97 |year=2004 |pmid=15056044 |doi=10.1586/14760584.3.4.S189}}</ref> | *Although ribavirin is more effective when administered early in the course of the disease (first 6 days of symptom onset) than when administered late, the benefit of ribavirin outweighs the risk of its adverse effects at any point during the illness, and administration of ribavirin is recommended at any time during the infection.<ref name="pmid3940312">{{cite journal| author=McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM et al.| title=Lassa fever. Effective therapy with ribavirin. | journal=N Engl J Med | year= 1986 | volume= 314 | issue= 1 | pages= 20-6 | pmid=3940312 | doi=10.1056/NEJM198601023140104 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3940312 }} </ref><ref name="who">Fact sheet N°179: Lassa Fever. World Health Organization. [http://www.who.int/mediacentre/factsheets/fs179/en/ Accessed on June 09, 2015.] </ref> | ||
*Compared with oral ribavirin, intravenous (IV) ribavirin is almost twice as [[effective dose|effective]]. It is thought, however, that the efficacy of IV ribavirin may, at least in part, be attributed to the decreased tolerance for oral intake among high-risk symptomatic groups (e.g. patients with gastrointestinal or neurological disease).<ref>{{cite journal |author=Fisher-Hoch SP, McCormick JB |title=Lassa fever vaccine |journal=Expert review of vaccines |volume=3 |issue=2 |pages=189-97 |year=2004 |pmid=15056044 |doi=10.1586/14760584.3.4.S189}}</ref> | |||
*The efficacy of ribavirin is more pronounced among symptomatic patients with signs of Lassa fever-related liver injury (i.e. AST > 150 IU/L)<ref name="pmid3940312">{{cite journal| author=McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM et al.| title=Lassa fever. Effective therapy with ribavirin. | journal=N Engl J Med | year= 1986 | volume= 314 | issue= 1 | pages= 20-6 | pmid=3940312 | doi=10.1056/NEJM198601023140104 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3940312 }} </ref> | |||
*Use of IV followed by oral ribavirin may be considered.<ref name="pmid3940312">{{cite journal| author=McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM et al.| title=Lassa fever. Effective therapy with ribavirin. | journal=N Engl J Med | year= 1986 | volume= 314 | issue= 1 | pages= 20-6 | pmid=3940312 | doi=10.1056/NEJM198601023140104 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3940312 }} </ref> | |||
*The efficacy of ribavirin for the post-exposure prophylaxis is unknown.<ref name="pmid3940312">{{cite journal| author=McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM et al.| title=Lassa fever. Effective therapy with ribavirin. | journal=N Engl J Med | year= 1986 | volume= 314 | issue= 1 | pages= 20-6 | pmid=3940312 | doi=10.1056/NEJM198601023140104 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3940312 }} </ref> | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" | {| style="border: 0px; font-size: 90%; margin: 3px;" | ||
| Line 16: | Line 21: | ||
| align="center" style="background:#4479BA; padding: 3px;" |{{fontcolor|#FFF|'''Optimal Treatment'''}} | | align="center" style="background:#4479BA; padding: 3px;" |{{fontcolor|#FFF|'''Optimal Treatment'''}} | ||
|- | |- | ||
| align="left" style="background:#efefef; padding: 10px;" |'''Ribavarin'''<ref name="pmid11988060">{{cite journal| author=Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB et al.| title=Hemorrhagic fever viruses as biological weapons: medical and public health management. | journal=JAMA | year= 2002 | volume= 287 | issue= 18 | pages= 2391-405 | pmid=11988060 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11988060 }} </ref> | | align="left" style="background:#efefef; padding: 10px;" |'''Ribavarin'''<ref name="pmid3940312">{{cite journal| author=McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM et al.| title=Lassa fever. Effective therapy with ribavirin. | journal=N Engl J Med | year= 1986 | volume= 314 | issue= 1 | pages= 20-6 | pmid=3940312 | doi=10.1056/NEJM198601023140104 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3940312 }} </ref><ref name="pmid11988060">{{cite journal| author=Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB et al.| title=Hemorrhagic fever viruses as biological weapons: medical and public health management. | journal=JAMA | year= 2002 | volume= 287 | issue= 18 | pages= 2391-405 | pmid=11988060 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11988060 }} </ref> | ||
*{{fontcolor|#4479BA|''Loading dose:''}} 30 mg/kg (max. 2g) IV<br> | *{{fontcolor|#4479BA|''Loading dose:''}} 30 mg/kg (max. 2g) IV<br> | ||
*{{fontcolor|#4479BA|''Concentration dose:''}} 16 mg/kg (max. 1g) IV q6h for 4 days, then 8 mg/kg (max. 500mg) IV q8h for 6 days | *{{fontcolor|#4479BA|''Concentration dose:''}} 16 mg/kg (max. 1g) IV q6h for 4 days, then 8 mg/kg (max. 500mg) IV q8h for 6 days | ||
| Line 23: | Line 28: | ||
==Pregnancy== | ==Pregnancy== | ||
* For 3rd-term pregnant women with Lassa fever, the risk of death is very high | *There are no randomized data on the efficacy of ribavirin among pregnant women. | ||
* For 3rd-term pregnant women with Lassa fever, the risk of death is very high. Among these patients, emergent evacuation of the uterus (by induction or surgically) has been demonstrated to decrease the risk of death.<ref>{{cite journal |author=Price ME, Fisher-Hoch SP, Craven RB, McCormick JB |title=A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy |journal=BMJ |volume=297 |issue=6648 |pages=584–7 |year=1988 |pmid=3139220 |url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=3139220}}</ref> | |||
*It is hypothesized that evacuating the uterus decreases the viral load significantly as the virus has high affinity for the [[placenta]] and other highly [[vascular]] tissues. | |||
*Observational studies have demonstrated that the [[fetus]] has only a one in ten chance of survival irrespective of the therapies used or the interventions attempted. | |||
*The main focus is on reducing the risk of death in the mother. Following active obstetrical intervention, treatment with ribavirin should be initiated immediately. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Viral diseases]] | [[Category:Viral diseases]] | ||
[[Category:Viruses]] | [[Category:Viruses]] | ||
| Line 35: | Line 43: | ||
[[Category:Tropical disease]] | [[Category:Tropical disease]] | ||
[[Category:Biological weapons]] | [[Category:Biological weapons]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 18:08, 18 September 2017
|
Lassa fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Lassa fever medical therapy On the Web |
|
American Roentgen Ray Society Images of Lassa fever medical therapy |
|
Risk calculators and risk factors for Lassa fever medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.; Ammu Susheela, M.D. [2]
Overview
Management of Lassa fever includes supportive care and administration of intravenous (IV) ribavirin. Data on the efficacy of antiviral agents in Lassa fever are scarce. IV ribavirin was previously evaluated for treatment of Lassa fever and demonstrated a reduction in mortality when administered anytime during the course of the disease, especially early within the first 6 days of symptom-onset. Ribavirin is administered intravenously for a total of 10 days using the following regimen: first, loading dose of 30 mg/kg (max. 2g) followed by a dose of 16 mg/kg (max. 1g) IV q6h for 4 days, followed by a dose of 8 mg/kg (max. 500mg) IV q8h for 6 days.[1] In addition to antiviral therapy, management includes supportive care to adequately maintain respiratory status, as well as fluid and electrolyte balance.
Medical Therapy
Supportive Care
- All hospitalized individuals with suspected Lassa fever should be isolated with proper disposal of body fluids and excreta.
- Supportive care, including adequate fluid and electrolyte replacement and blood transfusions, may also be required.
Antiviral Therapy: Ribavirin
- Intravenous (IV) ribavirin, an antiviral agent with an effect on viral replication, is associated with a reduction in mortality among patients with Lassa fever, especially when administered within the first 6 days of symptom-onset.[1]
- Although ribavirin is more effective when administered early in the course of the disease (first 6 days of symptom onset) than when administered late, the benefit of ribavirin outweighs the risk of its adverse effects at any point during the illness, and administration of ribavirin is recommended at any time during the infection.[1][2]
- Compared with oral ribavirin, intravenous (IV) ribavirin is almost twice as effective. It is thought, however, that the efficacy of IV ribavirin may, at least in part, be attributed to the decreased tolerance for oral intake among high-risk symptomatic groups (e.g. patients with gastrointestinal or neurological disease).[3]
- The efficacy of ribavirin is more pronounced among symptomatic patients with signs of Lassa fever-related liver injury (i.e. AST > 150 IU/L)[1]
- Use of IV followed by oral ribavirin may be considered.[1]
- The efficacy of ribavirin for the post-exposure prophylaxis is unknown.[1]
| Optimal Treatment |
Ribavarin[1][4]
|
Pregnancy
- There are no randomized data on the efficacy of ribavirin among pregnant women.
- For 3rd-term pregnant women with Lassa fever, the risk of death is very high. Among these patients, emergent evacuation of the uterus (by induction or surgically) has been demonstrated to decrease the risk of death.[5]
- It is hypothesized that evacuating the uterus decreases the viral load significantly as the virus has high affinity for the placenta and other highly vascular tissues.
- Observational studies have demonstrated that the fetus has only a one in ten chance of survival irrespective of the therapies used or the interventions attempted.
- The main focus is on reducing the risk of death in the mother. Following active obstetrical intervention, treatment with ribavirin should be initiated immediately.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM; et al. (1986). "Lassa fever. Effective therapy with ribavirin". N Engl J Med. 314 (1): 20–6. doi:10.1056/NEJM198601023140104. PMID 3940312.
- ↑ Fact sheet N°179: Lassa Fever. World Health Organization. Accessed on June 09, 2015.
- ↑ Fisher-Hoch SP, McCormick JB (2004). "Lassa fever vaccine". Expert review of vaccines. 3 (2): 189–97. doi:10.1586/14760584.3.4.S189. PMID 15056044.
- ↑ Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB; et al. (2002). "Hemorrhagic fever viruses as biological weapons: medical and public health management". JAMA. 287 (18): 2391–405. PMID 11988060.
- ↑ Price ME, Fisher-Hoch SP, Craven RB, McCormick JB (1988). "A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy". BMJ. 297 (6648): 584–7. PMID 3139220.